Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Oct 1, 2026 - P2 | N=120 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Oct 2030 ➔ Nov 2036 | Trial primary completion date: Mar 2027 ➔ Nov 2028
Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Small Lymphocytic Lymphoma • CCND1 • CD20 • CD5 • FCER2
|